Evidence map›Paper›PMID 42406789›Full record

ArticlePloS one2026

A multi-country qualitative evaluation of rapid mortality surveillance during the COVID-19 pandemic.

Carlie Congdon, Farnaz Malik, Ruxana Jina, Diana Kumar, Philip W Setel

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Carlie CongdonCivil Registration and Vital Statistics Program, Vital Strategies, New York, New York, United States of America.ORCID https://orcid.org/0000-0003-4420-7452
Farnaz MalikData Impact Program, Vital Strategies, New York, New York, United States of America.
Ruxana JinaData Impact Program, Vital Strategies, New York, New York, United States of America.
Diana KumarCivil Registration and Vital Statistics Program, Vital Strategies, New York, New York, United States of America.
Philip W SetelCivil Registration and Vital Statistics Program, Vital Strategies, New York, New York, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLow- and middle-income countries without well-functioning civil registration and vital statistics (CRVS) systems struggle to obtain accurate and complete counts of total (i.e., all-cause) mortality, especially during a pandemic. The aim of this evaluation was to assess whether rapid mortality surveillance (RMS) provided timely and useful counts of deaths to inform pandemic response, despite competing demands on government and public health responders, during the COVID-19 pandemic. This is the first published evaluation of efforts to test the feasibility, utility, and impact of efforts to improve or establish mortality surveillance.

methodsWe supported 13 low- and middle-income countries to implement RMS during the first wave of the COVID-19 pandemic. From August to October 2021, we conducted a qualitative assessment of each country's progress.

resultsAnalysis of in-depth interviews with 16 respondents in 13 countries surfaced common themes related to facilitators of RMS implementation. These include 1) government ownership and buy-in; 2) data collection and digitalization; 3) interagency collaboration and data sharing; 4) data analysis and interpretation; and 5) data use for decision-making.

conclusionRobust and digitalized CRVS systems can serve the rapid mortality surveillance function well. For locations where digitalization and connectivity of systems are still improving, more feasible and fit-for-purpose approaches are needed. These findings should inform the development of CRVS mortality surveillance functions in low- and middle-income countries.

Indexed as

COVID-19Population SurveillanceDeveloping CountriesHumansPandemicsSARS-CoV-2

Identifiers

PMID42406789
PMCPMC13336173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.